We wish to comment on the December 2015 article of Ramalho et al[1][1] entitled “Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update” in the American Journal of Neuroradiology . First, the authors introduced the study of Stojanov et al,[2][2] in which gadobutrol (Gadavist;
No takes yet. Share an insight, caveat, or question.
Kanda et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: